Clinical Trial Update: An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies [EARLY_Phase 1]

View source ↗

Summary

This open-label, single-arm Phase 1 study is currently recruiting to evaluate the safety and preliminary efficacy of OriV508 injections in adults with relapsed/…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• OriV508 Injection (OriV508)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) | EARLY_Phase 1 | Status: RECRUITING